Avidity Biosciences

RNA

Market cap $10.8B

“Big mo” stock strategies have lost their advantage, but these companies display relative strength.

SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) in the United States. "We recognize the considerable needs facing the DMD44 community given there are no approved exon skipping therapies for this disease as well as the potential of del-zota based on the unprecedented data shown in our clinical studies," said Sarah Boyce, President and Chief Executive Officer of Avidity.

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $0.65 per share a year ago.

Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ("SpinCo") Clear path forward aligned with FDA following pre-BLA meeting for del-zota, with BLA submission planned for 2026 Del-zota one-year data demonstrated sustained muscle protection leading to meaningful improvement and reversal of disease progression across multiple key functional measures Strong balance sheet with ~$1.9 billion  in cash, cash equivalents, and marketable securities SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent progress. "In October, we announced that Avidity entered into a definitive merger agreement with Novartis, which we believe maximizes value for our investors, accelerates the global reach of our innovative neuroscience pipeline, and advances even more possibilities for our innovative science," said Sarah Boyce, president and chief executive officer of Avidity.

Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity.

Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

MILWAUKEE , Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.